SCHEMBL687964

SCHEMBL687964

CCOc1cccc([C@H](CC(=O)O)NC(=O)Nc2c(O)c(C)c(C)n(Cc3c(C)cccc3Cl)c2=O)c1

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.40
FFAR1 O14842 3/20 0.37
PYGL P06737 1/20 0.34
NPSR1 Q6W5P4 2/20 0.34
RXFP1 Q9HBX9 1/20 0.34
CTSA P10619 5/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
LCK P06239 1/20 0.33
CYP26A1 O43174 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL686800 0.93 PPARG (0.41) PPARGFFAR1NPSR1RXFP1CTSA
SCHEMBL27741938 0.91 SMN1; SMN2 (0.42) NPSR1RXFP1CTSASMN1; SMN2
SCHEMBL687967 0.91 SMN1; SMN2 (0.42) NPSR1RXFP1CTSASMN1; SMN2
SCHEMBL688409 0.90 PPARG (0.42) PPARGFFAR1NPSR1RXFP1SMN1; SMN2
SCHEMBL686965 0.88 PPARG (0.40) PPARGFFAR1SMN1; SMN2CYP3A4
SCHEMBL687858 0.88 MEN1 (0.37) PPARGFFAR1PYGLNPSR1RXFP1
SCHEMBL693144 0.87 KDM4E (0.37) FFAR1PYGLNPSR1RXFP1CTSA
SCHEMBL688543 0.87 SMN1; SMN2 (0.38) PPARGNPSR1RXFP1CTSASMN1; SMN2
SCHEMBL688875 0.87 SMN1; SMN2 (0.37) PPARGFFAR1NPSR1RXFP1CTSA
SCHEMBL27741949 0.87 PPARG (0.38) PPARGSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1203766-B1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC (US) 2012-02-29 EP disclosed
EP-1203766-A2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors TEXAS BIOTECHNOLOGY CORPORATION (US) 2002-05-08 EP disclosed